GlassScriptPhysician profile
Eyad Abochale
NPI 1376577387
$11,343.41
in general payments reported to CMS, 2019-2025
42 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,565 · 2020: $1,219 · 2021: $1,528 · 2022: $1,732 · 2023: $1,651 · 2024: $1,918 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,300.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,517.87 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,985.37 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,557.50 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $1,010.27 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $744.76 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $664.21 | 2019-2024 | Yupelri |
| Genzyme Corporation | $627.42 | 2020-2025 | |
| Insmed, INC. | $191.49 | 2019-2025 | Arikayce, Brinsupri |
| Pfizer INC. | $170.96 | 2019-2024 | |
| Baxter Healthcare | $165.87 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $153.82 | 2020-2025 | Glassia |
| Intuitive Surgical, INC. | $134.44 | 2024 | |
| Merck Sharp & Dohme LLC | $118.65 | 2019-2024 | Zerbaxa |
| Bayer Healthcare Pharmaceuticals INC. | $118.21 | 2019-2022 | |
| Viatris Specialty LLC | $109.06 | 2025 | Yupelri |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eyad Abochale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.